Cytodyn Inc (CYDY)

[Gasman47]

Your logic is flawed. You assume that the placebo group stays within their (your) defined group of mortality rates. In fact, the critical/excluded group with the higher mortality had passed thru the lesser mortality rate group on their way to the more critical group. They obviously would have been part of the sever/critical group that could have been inserted into the trial if they had the chance to. The placebo group no doubt had recoveries but they also had progression into a more critical/excluded group, and then unfortunately would have the greater than 32% mortality. Leronlimab’s challenge is to keep the severe/critical group from going into the more critical group that would have the higher mortality. This is where the results will either show LL works or doesn’t.
So your inference that the Plcebo group would have a lower mortality rate is clearly flawed.